U.S. Markets open in 4 hrs 43 mins

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, MCHP, ABBV, ALNY and CHGG

NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.      

OPKO Health Inc. (OPK)
Class Period: September 26, 2013 to September 7, 2018
Lead Plaintiff Deadline: November 13, 2018

Throughout the class period, OPKO Health Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) OPKO and its Chairman and Chief Executive Officer, Phillip Frost, were engaged in a pump-and-dump scheme with several other individuals and companies in their investments in several penny stocks; (2) this illicit scheme would result in governmental scrutiny including from the SEC; and (3) as a result, defendants’ statements about OPKO’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the OPK lawsuit: http://www.kleinstocklaw.com/pslra-1/opko-health-inc-loss-submission-form?wire=3

Microchip Technology Inc. (MCHP)
Class Period: March 2, 2018 to August 9, 2018
Lead Plaintiff Deadline: November 16, 2018

The lawsuit alleges Microchip Technology Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) Microsemi’s financial performance was underperforming Microchip’s expectations; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, including positive statements about Microsemi, were materially misleading and/or lacked a reasonable basis.

Get additional information about the MCHP lawsuit: http://www.kleinstocklaw.com/pslra-1/microchip-technology-inc-loss-submission-form?wire=3

AbbVie Inc. (ABBV)
Class Period: October 25, 2013 to September 18, 2018
Lead Plaintiff Deadline: November 20, 2018

During the class period, AbbVie Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, relied in part upon illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would foreseeably lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Get additional information about the ABBV lawsuit: http://www.kleinstocklaw.com/pslra-1/abbvie-inc-loss-submission-form?wire=3

Alnylam Pharmaceuticals, Inc. (ALNY)
Class Period: February 15, 2018 to September 12, 2018
Lead Plaintiff Deadline: November 26, 2018

The lawsuit alleges that Alnylam Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.

Get additional information about the ALNY lawsuit: http://www.kleinstocklaw.com/pslra-1/alnylam-pharmaceuticals-inc-loss-submission-form?wire=3

Chegg, Inc. (CHGG)
Class Period: July 30, 2018 to September 25, 2018
Lead Plaintiff Deadline: November 26, 2018

The complaint alleges that during the class period Chegg, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate security measures to protect users’ data; (2)  the Company lacked the internal controls and procedures to detect unauthorized access to its systems and to its data; (3)  as a result, the Company would incur additional expenses and litigation risks; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the CHGG lawsuit: http://www.kleinstocklaw.com/pslra-1/chegg-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com